Getting it right: industry sponsorship and medical research.

Many of the policies and procedures for the ethical oversight of research were put in place in an era when public funding was much more prominent than it is now. Over the last 2 decades there have been major changes, with increasing pressure on universities, teaching hospitals and individual

[1]  Alan E. Bernstein.  Toward effective Canadian public-private partnerships in health research. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[3]  I. Banks,et al.  The pharmaceutical industry as an informant , 2003, The Lancet.

[4]  J. Abraham.  The pharmaceutical industry as a political player , 2002, The Lancet.

[5]  R. Califf,et al.  A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. , 2002, The New England journal of medicine.

[6]  D. Weatherall,et al.  Academic freedom in clinical research. , 2002, The New England journal of medicine.

[7]  Jeffrey M Drazen,et al.  Institutions, contracts, and academic freedom. , 2002, The New England journal of medicine.

[8]  E. Braunwald,et al.  Collaborating with industry--choices for the academic medical center. , 2002, The New England journal of medicine.

[9]  T. Lancet.  The next step: ensuring integrity of scientific research , 2002, The Lancet.

[10]  J. Lenzer.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. , 2002, BMJ : British Medical Journal.

[11]  J. Bevan.  Ethical behaviour of authors in biomedical journalism. , 2002, Annals.

[12]  R. Steinbrook.  Protecting research subjects--the crisis at Johns Hopkins. , 2002, The New England journal of medicine.

[13]  C. Naylor.  Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[15]  R. Kelch.  Maintaining the public trust in clinical research. , 2002, The New England journal of medicine.

[16]  J. Montaner,et al.  Industry-sponsored clinical research: a double-edged sword , 2001, The Lancet.

[17]  W. Ghali,et al.  Dancing with the porcupine: rules for governing the university-industry relationship. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  R. Horton,et al.  [Sponsorship, authorship and accountability]. , 2001, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[19]  R Smith,et al.  Maintaining the integrity of the scientific record , 2001, BMJ : British Medical Journal.

[20]  S. Morgan,et al.  Health economists meet the fourth tempter: drug dependency and scientific discourse. , 2000, Health economics.

[21]  T. Bodenheimer,et al.  Uneasy alliance--clinical investigators and the pharmaceutical industry. , 2000, The New England journal of medicine.

[22]  E. Marshal.  FDA Halts All Gene Therapy Trials at Penn , 2000, Science.

[23]  D. Rennie.  Fair conduct and fair reporting of clinical trials. , 1999, JAMA.

[24]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[25]  A. Skolnick.  Drug firm suit fails to halt publication of Canadian Health Technology Report. , 1998, JAMA.

[26]  L. Opie.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[27]  R. Simes,et al.  Publication bias: evidence of delayed publication in a cohort study of clinical research projects , 1997, BMJ.

[28]  G. Omenn,et al.  The messenger under attack -- intimidation of researchers by special-interest groups. , 1997, The New England journal of medicine.

[29]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[30]  I Chalmers,et al.  Underreporting research is scientific misconduct. , 1990, JAMA.

[31]  J. Beasley.  The treatment of obesity in adults. , 1989, JAMA.

[32]  P. Gøtzsche.  Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. , 1989, Controlled clinical trials.

[33]  Is the university–industrial complex out of control? , 2001, Nature.

[34]  E. Marshall.  FDA halts all gene therapy trials at Penn. , 2000, Science.